A multicenter phase II study of sorafenib, capecitabine, and oxaliplatin (SECOX) in patients with advanced hepatocellular carcinoma: Final results of Hong Kong-Singapore Hepatocellular Carcinoma Research Collaborative Group study.
Thomas Cheung Yau
Consultant or Advisory Role - Bayer Schering Pharma (U)
Foon Yiu Cheung
No relevant relationships to disclose
Francis Lee
No relevant relationships to disclose
Su Pin Choo
No relevant relationships to disclose
Hilda Wong
No relevant relationships to disclose
Han Chong Toh
No relevant relationships to disclose
A. K. Leung
No relevant relationships to disclose
Pierre Chan
No relevant relationships to disclose
T. K. Yau
No relevant relationships to disclose
Joyce Wong
No relevant relationships to disclose
Y. F. Tang
No relevant relationships to disclose
Sze Man June Lau
No relevant relationships to disclose
Tan To Cheung
No relevant relationships to disclose
Sheung Tat Fan
No relevant relationships to disclose
Ronnie Tung Ping Poon
Consultant or Advisory Role - Bayer Schering Pharma (U); Sanofi (U)